The FTSE 100 company, which has a market capitalisation of £185.9 billion, confirmed the deal in an announcement to the ...

Investment includes agreements with Harbour BioMed, Syneron Bio and BioKangtai
.

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts across multiple therapeutic areas expected in 2025 ...

[BEIJING] AstraZeneca will invest US$2.5 billion in a new research ... In January, Astra said it had received an appraisal opinion from the Shenzhen city customs office regarding suspected unpaid ...

Also Read: Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca’s Asthma Drug On Efficacy, Analysts Say Treatment with Tezspire significantly reduced nasal polyp severity: the Nasal ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...